Recently, Eprenetapopt received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA for the treatment of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who have mutant TP53, in combination with the nucleoside analog azacitidine [15]. This evidence concerns the gene TP53 and myelodysplastic syndrome.